The U.S. Food and Drug Administration (FDA) has expanded the use of Keytruda (pembrolizumab) as a second-line treatment for adults with relapsed or refractory classical Hodgkin’s lymphoma (cHL) for whom initial therapies did not work or stopped working. The regulatory agency also updated an indication for children and adolescents with cHL, who may now be prescribed Keytruda after failing to respond (refractory) to at least one prior treatment, or when their cancer returns after a successful initial…
You must be logged in to read/download the full post.
The post FDA Approves Keytruda for Adults as Second-Line Therapy for Hodgkin’s Lymphoma appeared first on BioNewsFeeds.